within Pharmacolibrary.Drugs.ATC.J;

model J05AP04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.23333333333333334,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.16,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 30.0
  );

  annotation(Documentation(
    info ="<html><body><p>Faldaprevir is a protease inhibitor developed as an antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection. It inhibits the HCV NS3/4A protease, a key enzyme in the viral replication process. Faldaprevir was investigated in clinical trials but has not been approved or marketed due to cessation of its development.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sabo, JP, et al., &amp; Huang, F (2015). Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. <i>Antimicrobial agents and chemotherapy</i> 59(1) 514–519. DOI:<a href=&quot;https://doi.org/10.1128/AAC.03589-14&quot;>10.1128/AAC.03589-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25385099/&quot;>https://pubmed.ncbi.nlm.nih.gov/25385099</a></p></li><li><p>Joseph, D, et al., &amp; Huang, F (2015). Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. <i>Antimicrobial agents and chemotherapy</i> 59(1) 498–504. DOI:<a href=&quot;https://doi.org/10.1128/AAC.04046-14&quot;>10.1128/AAC.04046-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25385094/&quot;>https://pubmed.ncbi.nlm.nih.gov/25385094</a></p></li><li><p>Huang, F, et al., &amp; Elgadi, M (2015). Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment. <i>Antimicrobial agents and chemotherapy</i> 59(1) 251–257. DOI:<a href=&quot;https://doi.org/10.1128/AAC.03359-14&quot;>10.1128/AAC.03359-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25348520/&quot;>https://pubmed.ncbi.nlm.nih.gov/25348520</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP04;
